Table 3.

Nanostructured lipid carrier–based antimalarial formulations

Drug	Formulation	ROA	Comments	Reference
Artemether	NLC	Intranasal (i.n.)	Significantly high concentration attained in 6 h following administration i.n. route due to slow drug release	[36]
Artemether	NLC	i.v.	Exhibits greater (P < 0.005) antimalarial activity than injectable marketed formulation, 60% survival rate was achieved after 31 days	[37]
Artemether-lumefantrine	NLC	Oral	Higher antimalarial activity in terms of parasitemia progression and period of survival	[38]
Artemether-lumefantrine	NLC	i.v.	Sustained drug release and complete parasitic clearance and reversal of symptoms of CM, with 100% survival in the mice infected with P. berghei	[39]
Artemether		i.v.	Cell line (HEK 293 T) cytotoxicity studies revealed that NLCs are non-toxic. Recrudescence of Plasmodium is prevented after the administration of the formulation. Apart from these, NLCs showed greater parasite clearance and better survival (60%) as compared with artemether solution (40%).	[40]